share_log

Despite Design Therapeutics' Pullback, Insiders Still Gained US$39k

Despite Design Therapeutics' Pullback, Insiders Still Gained US$39k

儘管Design Therapeutics出現回撤,高管們仍然獲得了39,000美元的收益。
Simply Wall St ·  01/09 10:00

Insiders who bought Design Therapeutics, Inc. (NASDAQ:DSGN) in the last 12 months may probably not pay attention to the stock's recent 18% drop. Even after accounting for the recent loss, the US$104.6k worth of stock purchased by them is now worth US$143.4k or in other words, their investment continues to give good returns.

在過去12個月裏,購買了Design Therapeutics, Inc.(納斯達克:DSGN)的內部人士可能不會關注該股票最近18%的下跌。即使考慮到近期的損失,他們所購買價值10.46萬美元的股票現在價值14.34萬美元,換句話說,他們的投資仍然有良好的回報。

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

雖然內部交易在長期投資中並不是最重要的,但是我們認爲關注內部人士的動向是完全合理的。

Design Therapeutics Insider Transactions Over The Last Year

Design Therapeutics過去一年的內部交易

Over the last year, we can see that the biggest insider purchase was by Independent Director John Schmid for US$100k worth of shares, at about US$3.74 per share. We do like to see buying, but this purchase was made at well below the current price of US$5.08. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

在過去一年中,我們看到最大的內部購買是由獨立董事約翰·施密德以價值10萬美元的股份進行的,價格約爲每股3.74美元。我們確實喜歡看到購買,但這一購買是在遠低於當前價格5.08美元的情況下進行的。雖然這表明內部人士認爲股票在低價時被低估,但此交易並沒有告訴我們他們對當前價格的看法。

Over the last year, we can see that insiders have bought 28.27k shares worth US$105k. On the other hand they divested 3.81k shares, for US$24k. In the last twelve months there was more buying than selling by Design Therapeutics insiders. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

在過去的一年裏,我們看到內部人士購買了2.827萬股,價值10.5萬美元。另一方面,他們出售了0.381萬股,價值2.4萬美元。在過去的十二個月中,Design Therapeutics的內部人士的購買多於銷售。下面的圖表顯示了過去一年的內部交易(按公司和個人)。如果您想確切知道是誰出售了,出售了多少錢,以及何時出售,只需點擊下面的圖表!

big
NasdaqGS:DSGN Insider Trading Volume January 9th 2025
納斯達克GS:DSGN 內部交易成交量 2025年1月9日

Design Therapeutics is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

設計治療公司並不是內部人士唯一購買的股票。對於那些喜歡尋找估值吸引的小盤公司的人來說,這份近期有內部人士購買的增長型公司免費名單,可能正是合適的選擇。

Insiders At Design Therapeutics Have Sold Stock Recently

設計治療公司的內部人士近期已出售股票

Over the last three months, we've seen a bit of insider selling at Design Therapeutics. Independent Director Deepa Prasad only netted US$24k selling shares, in that period. Neither the lack of buying nor the presence of selling is heartening. But the amount sold isn't enough for us to put any weight on it.

在過去的三個月裏,我們看到設計治療公司有一些內部人士的減持。獨立董事Deepa Prasad在此期間僅通過出售股份獲得了24,000美元的收益。沒有購買的情況以及出售的存在令人爲之沮喪。但出售的數量不足以讓我們對此給予過多關注。

Does Design Therapeutics Boast High Insider Ownership?

設計治療公司是否擁有較高的內部持股?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. It appears that Design Therapeutics insiders own 16% of the company, worth about US$52m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

測試公司領導與其他股東之間的對齊程度的另一種方法是看他們擁有多少股票。我認爲,如果內部人持有大量公司的股份,那是一個好跡象。據顯示,Design Therapeutics的內部人擁有公司16%的股份,價值約5200萬美元。我們在其他地方確實見過更高的內部人持股水平,但這些持股足以表明內部人與其他股東之間的對齊。

So What Do The Design Therapeutics Insider Transactions Indicate?

那麼,Design Therapeutics的內部交易表明了什麼?

While there has not been any insider buying in the last three months, there has been selling. However, the sales are not big enough to concern us at all. However, our analysis of transactions over the last year is heartening. Insiders own shares in Design Therapeutics and we see no evidence to suggest they are worried about the future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we've found that Design Therapeutics has 4 warning signs (2 are potentially serious!) that deserve your attention before going any further with your analysis.

雖然在過去三個月內沒有內部人買入,但卻有賣出。然而,這些銷售並不足以讓我們感到擔憂。儘管如此,我們對過去一年的交易分析是令人振奮的。內部人持有Design Therapeutics的股票,我們沒有看到任何證據表明他們對未來感到擔憂。雖然了解內部人的持股和交易情況是好的,但在做出任何投資決策之前,我們確保考慮股票面臨的風險。在Simply Wall ST,我們發現Design Therapeutics有4個警告信號(2個可能是嚴重的!)值得您在進一步分析之前引起注意。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,您也可能會在其他地方找到一個絕佳的投資。請查看這個免費的有趣公司名單。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

在本文中,內部人士是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 381

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。